JP2014507422A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507422A5
JP2014507422A5 JP2013551360A JP2013551360A JP2014507422A5 JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5 JP 2013551360 A JP2013551360 A JP 2013551360A JP 2013551360 A JP2013551360 A JP 2013551360A JP 2014507422 A5 JP2014507422 A5 JP 2014507422A5
Authority
JP
Japan
Prior art keywords
alkyl
group
formula
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013551360A
Other languages
English (en)
Japanese (ja)
Other versions
JP6000283B2 (ja
JP2014507422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/022847 external-priority patent/WO2012106188A1/en
Publication of JP2014507422A publication Critical patent/JP2014507422A/ja
Publication of JP2014507422A5 publication Critical patent/JP2014507422A5/ja
Application granted granted Critical
Publication of JP6000283B2 publication Critical patent/JP6000283B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013551360A 2011-01-31 2012-01-27 Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン Expired - Fee Related JP6000283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437870P 2011-01-31 2011-01-31
US61/437,870 2011-01-31
PCT/US2012/022847 WO2012106188A1 (en) 2011-01-31 2012-01-27 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2014507422A JP2014507422A (ja) 2014-03-27
JP2014507422A5 true JP2014507422A5 (zh) 2015-02-26
JP6000283B2 JP6000283B2 (ja) 2016-09-28

Family

ID=45567146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013551360A Expired - Fee Related JP6000283B2 (ja) 2011-01-31 2012-01-27 Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン

Country Status (19)

Country Link
US (1) US8748415B2 (zh)
EP (1) EP2670764B1 (zh)
JP (1) JP6000283B2 (zh)
CN (1) CN103339141B (zh)
BR (1) BR112014010105A2 (zh)
CA (1) CA2826257A1 (zh)
CY (1) CY1116989T1 (zh)
DK (1) DK2670764T3 (zh)
EA (1) EA023578B1 (zh)
ES (1) ES2552512T3 (zh)
HR (1) HRP20151212T1 (zh)
HU (1) HUE026371T2 (zh)
MX (1) MX2013008359A (zh)
PL (1) PL2670764T3 (zh)
PT (1) PT2670764E (zh)
RS (1) RS54352B1 (zh)
SI (1) SI2670764T1 (zh)
SM (1) SMT201500303B (zh)
WO (1) WO2012106188A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012312485B2 (en) 2011-09-21 2016-09-01 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
RU2516952C1 (ru) * 2012-11-09 2014-05-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные
RU2519133C1 (ru) * 2012-11-09 2014-06-10 Леонид Леонидович Клопотенко Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные
CN103214543B (zh) * 2012-12-25 2015-09-02 中国人民解放军海军医学研究所 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用
MX2015010003A (es) * 2013-02-06 2015-10-30 Squibb Bristol Myers Co Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MA39374A1 (fr) 2014-04-11 2018-06-29 Viiv Healthcare Uk No 4 Ltd Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
WO2015195776A1 (en) * 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CA2967684A1 (en) 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
US20180094019A1 (en) * 2015-04-14 2018-04-05 ViiV Healthcare UK (No.4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity
AU2016298669A1 (en) 2015-07-28 2018-02-22 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating HIV infections
WO2017017607A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
US20180273579A1 (en) 2015-09-24 2018-09-27 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
US20190023733A1 (en) 2016-01-20 2019-01-24 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2019055280A1 (en) * 2017-09-13 2019-03-21 Emmyon, Inc. DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
KR20210107904A (ko) 2017-09-14 2021-09-01 피닉스 바이오테크놀러지 인코포레이티드. 바이러스 감염 치료를 위한 조성물
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
WO2005090380A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
ZA200704806B (en) * 2004-11-12 2008-09-25 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
JP5752789B2 (ja) * 2010-06-04 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
RS54239B1 (en) * 2010-06-04 2015-12-31 Bristol-Myers Squibb Company C-28 MODIFIED C-3 BETULINIC ACID DERIVATIVES AS INHIBITORS OF HIV AGING
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Similar Documents

Publication Publication Date Title
JP2014507422A5 (zh)
JP2014503595A5 (zh)
JP2015510515A5 (zh)
JP2013527243A5 (zh)
JP2016509062A5 (zh)
JP2013527242A5 (zh)
HRP20151212T1 (hr) C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
JP2014526554A5 (zh)
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
JP2013507425A5 (zh)
JP2017505314A5 (zh)
HRP20180202T1 (hr) Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti
JP2012524055A5 (zh)
JP2018513150A5 (zh)
JP2013518832A5 (zh)
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
JP2004531531A5 (zh)
JP2017537949A5 (zh)
JP2011526924A5 (zh)
JP2013532660A5 (zh)
JP2013535426A5 (zh)
JP2020532545A5 (zh)
JP2014521744A5 (zh)
JP2009544708A5 (zh)